Clinical Trials

Clinical Trial Detail

Return to search results.

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Complete title: Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

Research Study Number       6932
Principal Investigator       Robert Montgomery, MD
Phase       NA

Look up trial at NIH

Research Study Description

This research trial collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate or bladder/urothelial cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat the cancer.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Male

Accepts Healthy Volunteers: Yes

Sampling Method: Non-Probability Sample

Study Population:

Patients with prostate or bladder/urothelial cancer treated in genitourinary oncology practices at University of Washington Medical Center, Seattle Cancer care Alliance and Harborview Medical Center and healthy controls

- Patients with localized and/or metastatic bladder/urothelial or prostate cancer who have disease in the primary organ, biopsy accessible bone metastases (collaborating radiologists will determine if bone metastasis is appropriate for biopsy) or soft tissue metastases are eligible; men and women without cancer are eligible to have blood or normal tissue collected if acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder); in patients without malignancy, no additional tissue beyond that necessary for care will be procured

- Ability to adequately understand and give informed consent

- Local or metastatic disease to soft tissue or bone at sites accessible to biopsy with minimal risk of complications

- Platelet count > 50,000

- White blood cell (WBC) > 1,500

- Hemoglobin (Hgb) > 8.0

- International normalized ratio (INR) < 1.5

- Partial thromboplastin time (PTT) < 45

- No history of excessive unexplained bleeding from previous surgery

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Patients unable to stop chronic anticoagulation with warfarin or Lovenox for less than 3 days

- Serious or uncontrolled infection

- Treatment with a vascular endothelial growth factor (VEGF) inhibitor (such as Avastin) within the past 28 days

Other exclusion criteria may apply.

Research Study Number       6932
Contact       Robert Montgomery, MD
Telephone       206/598-0860

Genitourinary Cancer; Prostate Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials